Antonia S, et al. Overall survival with durvalumab versus placebo after chemoradiotherapy in stage III NSCLC: updated results from PACIFIC. IASLC 2018, abstract PL02.01.
Durvalumab na chemoradiotherapie bij stadium III niet-kleincellig longcarcinoom
aug 2018 | Longoncologie